Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Target Product Profile Analysis of COVID-19 Vaccines in Phase III Clinical Trials and Beyond: An Early 2021 Perspective
Colin Funk, Craig A. Laferrière, Ali Ardakani
Viruses (2021) Vol. 13, Iss. 3, pp. 418-418
Open Access | Times Cited: 58

Showing 1-25 of 58 citing articles:

Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19
Brian J. Ward, Philipe Gobeil, Annie Séguin, et al.
Nature Medicine (2021) Vol. 27, Iss. 6, pp. 1071-1078
Open Access | Times Cited: 269
Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine
Karen Hager, Gonzalo Pérez Marc, Philipe Gobeil, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 22, pp. 2084-2096
Open Access | Times Cited: 173
Evaluation of Side Effects Associated with COVID-19 Vaccines in Saudi Arabia
Abdulaziz Alhazmi, Edrous Alamer, Dalia Daws, et al.
Vaccines (2021) Vol. 9, Iss. 6, pp. 674-674
Open Access | Times Cited: 155
A comprehensive review on COVID-19 vaccines: development, effectiveness, adverse effects, distribution and challenges
Md. Mijanur Rahman, Md. Habib Ullah Masum, Shah Wajed, et al.
VirusDisease (2022) Vol. 33, Iss. 1, pp. 1-22
Open Access | Times Cited: 98
COVID-19 hospitalisations in immunocompromised individuals in the Omicron era: a population-based observational study using surveillance data in British Columbia, Canada
Taraneh Bahremand, Jiayun Yao, Christopher Mill, et al.
The Lancet Regional Health - Americas (2023) Vol. 20, pp. 100461-100461
Open Access | Times Cited: 41
Forecasting fully vaccinated people against COVID-19 and examining future vaccination rate for herd immunity in the US, Asia, Europe, Africa, South America, and the World
Pınar Cihan
Applied Soft Computing (2021) Vol. 111, pp. 107708-107708
Open Access | Times Cited: 67
Modelling the DFT structural and reactivity study of feverfew and evaluation of its potential antiviral activity against COVID-19 using molecular docking and MD simulations
Shradha Lakhera, Kamal Devlal, Arabinda Ghosh, et al.
Chemical Papers (2022) Vol. 76, Iss. 5, pp. 2759-2776
Open Access | Times Cited: 46
Plant-made vaccines against viral diseases in humans and farm animals
Hang Su, André van Eerde, Espen Rimstad, et al.
Frontiers in Plant Science (2023) Vol. 14
Open Access | Times Cited: 31
Reported side-effects following Oxford/AstraZeneca COVID-19 vaccine in the north-west province, Iran: A cross-sectional study
Majid Eterafi, Nasrin Fouladi, Majid Golizadeh, et al.
PLoS ONE (2024) Vol. 19, Iss. 1, pp. e0296669-e0296669
Open Access | Times Cited: 9
Variants of Concern Are Overrepresented Among Postvaccination Breakthrough Infections of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Washington State
Abbye E. McEwen, Seth A. Cohen, Chloe Bryson‐Cahn, et al.
Clinical Infectious Diseases (2021) Vol. 74, Iss. 6, pp. 1089-1092
Open Access | Times Cited: 45
Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial
Rolando Ochoa-Azze, Arturo Chang Monteagudo, Yanet Climent-Ruíz, et al.
The Lancet Respiratory Medicine (2022) Vol. 10, Iss. 8, pp. 785-795
Open Access | Times Cited: 28
A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity
Sonia Pérez-Rodríguez, Meiby Rodríguez-González, Rolando Ochoa-Azze, et al.
Vaccine (2022) Vol. 40, Iss. 13, pp. 2068-2075
Open Access | Times Cited: 27
A Quadrivalent mRNA Immunization Elicits Potent Immune Responses against Multiple Orthopoxviral Antigens and Neutralization of Monkeypox Virus in Rodent Models
Caixia Su, Sha Li, Yang Wen, et al.
Vaccines (2024) Vol. 12, Iss. 4, pp. 385-385
Open Access | Times Cited: 6
A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial
Arturo Chang Monteagudo, Rolando Ochoa-Azze, Yanet Climent-Ruíz, et al.
The Lancet Regional Health - Americas (2021) Vol. 4, pp. 100079-100079
Open Access | Times Cited: 39
Phase 2 Randomized Trial of an AS03 Adjuvanted Plant-Based Virus-Like Particle Vaccine for Covid-19 in Healthy Adults, Older Adults and Adults with Comorbidities
Philipe Gobeil, Stéphane Pillet, Iohann Boulay, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Closed Access | Times Cited: 32
Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities
Nathalie Charland, Philipe Gobeil, Stéphane Pillet, et al.
npj Vaccines (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 25
Variants of concern are overrepresented among post-vaccination breakthrough infections of SARS-CoV-2 in Washington State
Abbye E. McEwen, Seth A. Cohen, Chloe Bryson‐Cahn, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 31
How Do Enveloped Viruses Exploit the Secretory Proprotein Convertases to Regulate Infectivity and Spread?
Nabil G. Seidah, Antonella Pasquato, Ursula Andréo
Viruses (2021) Vol. 13, Iss. 7, pp. 1229-1229
Open Access | Times Cited: 30
Side-effects of COVID-19 vaccines among the Saudi population
Ebtehaj Saud Almughais, Ali H. Alharbi, Hadi Aldarwish, et al.
Saudi Medical Journal (2022) Vol. 43, Iss. 4, pp. 386-393
Open Access | Times Cited: 21
Harnessing Nanovaccines for Effective Immunization─A Special Concern on COVID-19: Facts, Fidelity, and Future Prospective
Amol D. Gholap, Juhi Gupta, Pallavi Kamandar, et al.
ACS Biomaterials Science & Engineering (2023) Vol. 10, Iss. 1, pp. 271-297
Closed Access | Times Cited: 10
Plant-derived VLP: a worthy platform to produce vaccine against SARS-CoV-2
Mohsen Hemmati-Dinarvand, Mohsen Hemmati-Dinarvand, Marziye Karimzade, et al.
Biotechnology Letters (2021) Vol. 44, Iss. 1, pp. 45-57
Open Access | Times Cited: 26
The hindrances to perform the COVID-19 vaccination in Brazil
Matheus Negri Boschiero, Camila Vantini Capasso Palamim, Fernando Augusto Lima Marson
Human Vaccines & Immunotherapeutics (2021) Vol. 17, Iss. 11, pp. 3989-4004
Open Access | Times Cited: 25
Safety Profile of COVID-19 Vaccines among Healthcare Workers in Poland
Anna Paczkowska, Karolina Hoffmann, Michał Michalak, et al.
Vaccines (2022) Vol. 10, Iss. 3, pp. 434-434
Open Access | Times Cited: 14
Assessment of COVID-19 vaccination among healthcare workers in Iraq; adverse effects and hesitancy
Omeed Darweesh, Nasir Khatab, Ramiar Kamal Kheder, et al.
PLoS ONE (2022) Vol. 17, Iss. 11, pp. e0274526-e0274526
Open Access | Times Cited: 14
Immunogenicity and Safety of SARS-CoV-2 Protein Subunit Recombinant Vaccine (IndoVac®) as a Booster Dose against COVID-19 in Indonesian Adults
Kusnandi Rusmil, Eddy Fadlyana, Rodman Tarigan Girsang, et al.
Vaccines (2024) Vol. 12, Iss. 5, pp. 540-540
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top